Aliases & Classifications for Pollen Allergy

MalaCards integrated aliases for Pollen Allergy:

Name: Pollen Allergy 12 15
Hay Fever 70

Classifications:



External Ids:

Disease Ontology 12 DOID:0060497
UMLS 70 C0018621

Summaries for Pollen Allergy

Disease Ontology : 12 A respiratory allergy triggered by pollen.

MalaCards based summary : Pollen Allergy, also known as hay fever, is related to timothy grass allergy and ige responsiveness, atopic, and has symptoms including tinnitus, rhinorrhea and snoring. An important gene associated with Pollen Allergy is IL5 (Interleukin 5), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Histamine and Cetirizine have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and t cells, and related phenotypes are hematopoietic system and immune system

Wikipedia : 73 Allergic rhinitis, also known as hay fever, is a type of inflammation in the nose which occurs when the... more...

Related Diseases for Pollen Allergy

Diseases related to Pollen Allergy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 179)
# Related Disease Score Top Affiliating Genes
1 timothy grass allergy 31.2 RNASE3 PDCL PDC IL5 IL13
2 ige responsiveness, atopic 30.7 RNASE3 IL5 IL4R IL13 IGHE
3 allergic rhinitis 30.5 RNASE3 MPO IL5 IL4R IL13 IGHE
4 cytokine deficiency 30.5 IL5 IL13
5 exercise-induced bronchoconstriction 30.4 RNASE3 IL13
6 esophagitis 30.4 RNASE3 PRG2 IL5 IL13
7 rhinitis 30.3 RNASE3 PRG2 IL5 IL4R IL13 IGHE
8 peanut allergy 30.3 IL5 IL13 IGHE
9 conjunctivitis 30.3 RNASE3 MPO IL5 IL13 IGHE ICAM1
10 dermatitis 30.2 RNASE3 IL5 IL4R IL13 IGHE ICAM1
11 esophagitis, eosinophilic, 1 30.1 RNASE3 IL5 IL3 IL13 EPX
12 allergic asthma 30.0 RNASE3 IL5 IL4R IL3 IL13 IGHE
13 bronchitis 29.9 RNASE3 MPO IL5 IL13
14 allergic conjunctivitis 29.8 RNASE3 IL5 IL13 IGHE ICAM1 FOXP3
15 celery allergy 29.7 SCP2 GHITM
16 urticaria 29.7 RNASE3 PRG2 IL5 IL3 IL13 IGHE
17 apple allergy 29.5 SCP2 PDCL PDC
18 food allergy 29.5 SCP2 RNASE3 IL5 IL4R IL13 IGHE
19 allergic disease 29.4 RNASE3 PRG2 MPO IL5 IL4R IL3
20 dermatitis, atopic 29.3 RNASE3 PRG2 IL5 IL4R IL13 IGHE
21 peach allergy 29.3 SCP2 PDCL PDC IGHE ENPP3
22 chronic rhinitis 28.9 RNASE3 PRG2 MPO IL5 IL13 GHITM
23 nut allergy 28.9 SCP2 PDCL IL5 IL13 IGHE ENPP3
24 hypereosinophilic syndrome 28.9 RNASE3 PRG2 MPO IL5 IL3 IL13
25 asthma 28.8 RNASE3 PRG2 MPO IL5 IL4R IL3
26 respiratory allergy 28.4 SCP2 RNASE3 PDCL PDC IL5 IL4R
27 fruit allergy 28.1 SCP2 PDCL PDC IL5 IL13 GHITM
28 pemphigoid 10.4 IL5 IL13
29 aztreonam allergy 10.4 IL5 IL13
30 cefuroxime allergy 10.4 IL5 IL13
31 angioimmunoblastic lymphadenopathy with dysproteinemia 10.4 IL5 IL13
32 chromium allergic contact dermatitis 10.4 IL5 IL13
33 ceftriaxone allergy 10.4 IL5 IL13
34 respiratory syncytial virus infectious disease 10.4 IL5 IL13
35 loeffler syndrome 10.4 IL5 IL13
36 carbapenem allergy 10.4 IL13 ENPP3
37 exercise-induced anaphylaxis 10.4 IGHE ENPP3
38 aneruptive fever 10.3 IL13 FOXP3
39 mikulicz disease 10.3 IL5 IL13
40 chlorhexidine allergy 10.3 ENPP3 CD63
41 actinic prurigo 10.3 IL13 ICAM1
42 meningitis 10.3 IL5 IL13 ICAM1
43 cefaclor allergy 10.3 IL5 IL13 CD63
44 strongyloidiasis 10.3 IL5 IL13 IGHE
45 toxic oil syndrome 10.3 IL5 IGHE
46 eosinophilic meningitis 10.3 IL5 IL13 IGHE
47 autoimmune enteropathy 10.3 ICAM1 FOXP3
48 penicillin allergy 10.3 IL4R IL13 IGHE
49 vasomotor rhinitis 10.3 RNASE3 IL5 IL13
50 elephantiasis 10.3 RNASE3 IL5 IL13

Graphical network of the top 20 diseases related to Pollen Allergy:



Diseases related to Pollen Allergy

Symptoms & Phenotypes for Pollen Allergy

UMLS symptoms related to Pollen Allergy:


tinnitus; rhinorrhea; snoring; sore throat; coughing; vertigo/dizziness; equilibration disorder

MGI Mouse Phenotypes related to Pollen Allergy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.7 ADRB2 ENPP3 EPX FOXP3 ICAM1 IL13
2 immune system MP:0005387 9.4 ADRB2 ENPP3 EPX FOXP3 ICAM1 IL13

Drugs & Therapeutics for Pollen Allergy

Drugs for Pollen Allergy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 52)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
2
Cetirizine Approved Phase 4 83881-51-0 2678
3
Loratadine Approved, Investigational Phase 4 79794-75-5 3957
4
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
5 Neurotransmitter Agents Phase 4
6 Histamine Antagonists Phase 4
7 Dermatologic Agents Phase 4
8 Histamine H1 Antagonists, Non-Sedating Phase 4
9
Histamine Phosphate Phase 4 51-74-1 65513
10 Histamine H1 Antagonists Phase 4
11 Anti-Allergic Agents Phase 4
12 Anti-Asthmatic Agents Phase 4
13 Respiratory System Agents Phase 4
14 Bronchodilator Agents Phase 4
15 Anti-Inflammatory Agents Phase 4
16
Mannitol Approved, Investigational Phase 3 69-65-8 6251 453
17
Ciclesonide Approved, Investigational Phase 3 126544-47-6, 141845-82-1 444033
18
Aluminum hydroxide Approved, Investigational Phase 3 21645-51-2
19 Pharmaceutical Solutions Phase 3
20 Hormone Antagonists Phase 3
21 glucocorticoids Phase 3
22 Hormones Phase 3
23 Immunologic Factors Phase 3
24
Omalizumab Approved, Investigational Phase 2 242138-07-4
25
Coal tar Approved Phase 2 8007-45-2
26
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
27 Antibodies, Monoclonal Phase 2
28 Acidophilus Phase 1, Phase 2
29 Bifidobacterium Phase 1, Phase 2
30 Vaccines Phase 2
31
Phenol Approved, Experimental Phase 1 108-95-2 996
32 Monophosphoryl lipid A Phase 1
33
Ephedrine Approved 299-42-3 9294
34
Xylometazoline Approved, Investigational 526-36-3 5709
35
Pseudoephedrine Approved 90-82-4 7028
36
Chromium Approved 7440-47-3 27668
37
Heparin Approved, Investigational 9005-49-6 772 9812414
38
Iron Approved 7439-89-6 23925 29936
39
Vitamin A Approved, Nutraceutical, Vet_approved 68-26-8, 11103-57-4 445354
40 Nasal Decongestants
41 Vasoconstrictor Agents
42 Interleukin-12
43 Immunoglobulins, Intravenous
44 Immunoglobulin E
45 calcium heparin
46 Retinol palmitate
47 retinol
48 Iron Chelating Agents
49 Vitamins
50 Whey Protein

Interventional clinical trials:

(show top 50) (show all 51)
# Name Status NCT ID Phase Drugs
1 Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Zyrtec® (Cetirizine HCl) Syrup vs. Claritin® (Loratadine) Syrup vs. Placebo in Treatment of Children With Seasonal Allergic Rhinitis (SAR) Completed NCT02932774 Phase 4 Cetirizine;Loratadine
2 A Placebo Controlled, Double-Blind, Randomised Study to Assess Efficacy of Sublingual Immunotherapy in Patients With Grass Pollen Allergy Through Assessment of Its Immunological Effects on the Mucosal Tissue of the Nose. Completed NCT00150514 Phase 4 Oralgen
3 Comparison of the Effect of Fluticasone Furoate Nasal Spray Versus Placebo on Allergic Mediators in the Tears of Subjects With Tree or Grass Pollen Allergy Completed NCT00891436 Phase 4 Fluticasone furoate nasal spray;Placebo nasal spray
4 A Multicentre, International, Randomised, Double-blind, Placebo-controlled Study to Demonstrate the Clinical Efficacy and Safety of Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis Unknown status NCT03724240 Phase 3
5 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Clinical Trial Designed to Assess the Safety and Efficacy of Ciclesonide (200mcg and 100mcg, Once Daily) Applied as a Nasal Spray for Two Weeks in the Treatment of Seasonal Allergic Rhinitis (SAR) in Patients 6 to 11 Years of Age Completed NCT00305487 Phase 3 Ciclesonide nasal spray
6 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Clinical Trial Designed to Assess the Safety and Tolerability of Ciclesonide (200 mcg Once Daily), Applied as a Nasal Spray for Twelve Weeks, in the Treatment of Perennial Allergic Rhinitis (PAR) in Pediatric Patients 2-5 Years of Age Completed NCT00261287 Phase 3 Ciclesonide
7 A Multicenter, International, Randomised, Double-blind, Placebo Controlled Study to Demonstrate the Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis Completed NCT02560948 Phase 3
8 A Multicentre Randomised Placebo-controlled Double-blind Clinical Trial for Evaluation of Safety and Efficacy of Immunotherapy With an Aluminium Hydroxide-adsorbed Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen, Bet v 1 Completed NCT00309062 Phase 3
9 A Multicentre, Placebo-controlled, Double-blind Study to Evaluate Efficacy and Safety of a Perennial Sublingual Specific Immunotherapy With a Liquid Formulation of an Extract of a Six Grass Pollen-mixture in Patients With Clinically Relevant Grass Pollen Sensitivity. Completed NCT00264459 Phase 3
10 A Multicentre Randomised Placebo-controlled Double-blind Clinical Trial for Evaluation of Safety and Efficacy of Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Allergoid Preparation of Birch Pollen Allergens Completed NCT00263627 Phase 3
11 A Multicentre, Placebo Controlled, Double-Blind Study for Evaluation of Safety and Efficacy of Preseasonal Specific Immunotherapy With an Allergoid Preparation of an Extract of a 6 Grass Pollen Mixture in Patients With Clinically Relevant Grass Pollen Sensitivity Completed NCT00263601 Phase 3
12 Comparison of the Efficacy and the Safety of Different Schedules of Administration of Sub-lingual Immunotherapy in Patients With Ragweed Pollinosis: a Phase III Randomized and Controlled Clinical Study Completed NCT01500642 Phase 3
13 A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment Initiated in the Grass Pollen Season in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis Completed NCT00773240 Phase 3 Grazax;placebo
14 A Nasally Applied Cellulose Powder in Seasonal Allergic Rhinitis in Adults With Grass Pollen Allergy: A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group Study Completed NCT03039816 Phase 2, Phase 3
15 Two Center Evaluation of the Safety and Efficacy of Topical Nasal rEV131 Versus rEV131 Vehicle (Placebo)in the Prevention of the Signs and Symptoms of Allergic Rhinitis Induced by Nasal Allergen Challenge Unknown status NCT00247520 Phase 1, Phase 2 topical nasal rEV131
16 Preliminary Assessment of the Clinical Tolerability, Safety and Immunogenicity of Three Different Doses of Grass Pollen-derived Peptides for Oral Use in Antigen-specific Immunotherapy of Seasonal Allergic Rhinoconjunctivitis Completed NCT00833066 Phase 1, Phase 2
17 Safety, Clinical Tolerability and Immunogenicity of gpASIT+TM Administered Subcutaneously to Hay Fever Patients Either Alone or in Presence of DnaK Immunoregulating Adjuvant Completed NCT01506375 Phase 2
18 Safety, Clinical Tolerability and Immunogenicity of Increasing Doses of gpASIT+TM Administered Subcutaneously to Hay Fever Patients Completed NCT02156791 Phase 2
19 Efficacy and Safety Evaluation of Allergen Immunotherapy Co-Administered With Omalizumab, an Anti-IgE Monoclonal Antibody (ITN019AD) Completed NCT00078195 Phase 2
20 A Randomized Study to Evaluate a Novel Method of Specific Allergen Immunotherapy in Grass and/or Tree Pollen Allergic Subjects by Intralymphatic Allergen Administration Completed NCT00470457 Phase 2
21 A Bicentre Open Label Randomised Pilot Study for Proof of Safety and Efficacy of Immunotherapy With an Aluminium Hydroxide-adsorbed Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen Bet v 1-FV Versus a Depot Extract of Natural Birch Allergen Completed NCT00266526 Phase 2
22 Safety and Dose Finding Study Based on the Effects of Three Subcutaneous Injections of BM32, a Recombinant Hypoallergenic Grass Pollen Vaccine, on Responses to Allergen Challenge by Skin Testing and in the Vienna Challenge Chamber (VCC) as Well as Immunological Response in Subjects Know to Suffer From Grass-pollen Induced Allergic Rhinitis Completed NCT01445002 Phase 2
23 Phase IIb Study on the Safety and Efficacy of BM32, a Recombinant Hypoallergenic Vaccine for Immunotherapy of Grass Pollen Allergy Completed NCT01538979 Phase 2
24 A Dose-response Evaluation of ALK Tree AIT Completed NCT01675791 Phase 2
25 Clinical Efficacy, Immunogenicity, Clinical Tolerability and Assessment of Safety of gpASIT+TM Administered Orally, According to Two Administration Schedules, for the Prophylaxis of Seasonal Grass Pollen Rhinoconjunctivitis Completed NCT01308021 Phase 2
26 Safety, Immunogenicity and Clinical Efficacy of an Allergen Vaccine (CYT005-AllQbG10) in Subjects With Seasonal Rhinoconjunctivitis Due to Grass-Pollen Allergy Completed NCT00293904 Phase 1, Phase 2
27 A Multicentre Open Label Safety Study of a Sublingual Specific Immunotherapy With a Solution of Birch Pollen Allergen Extract in Patients With Clinically Relevant Birch Pollen Allergy Completed NCT00818181 Phase 2 Biological: AL0206st
28 Explorative Analysis of the Immunomodulatory Capacities of Apathogenic Escherichia Coli Nissle 1917 in Patients With Rhinoconjunctivitis Due to Grass Pollen Allergy Completed NCT01013259 Phase 2 Mutaflor;Placebo
29 Probiotic Intervention for Children With Birch Pollen Allergy Completed NCT00746226 Phase 1, Phase 2
30 Double Blind, Placebo-controlled, Dose Finding, Prospective, Multicenter Clinical Trial for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy Recruiting NCT02654223 Phase 2
31 A Double Blind Study to Investigate the Clinical Efficacy and Safety of TreeMATAMPL (Allergy Therapeutics, (UK) Ltd.), TreeMATA (Allergy Therapeutics, (UK) Ltd.) and Placebo in Patients With Seasonal Allergic Rhinitis Due to Birch Pollen Allergy, in an Environmental Exposure Chamber (EEC) Model When Exposed to Birch Pollen and Oak Pollen Terminated NCT00387478 Phase 2
32 Comparison of the Influence of Different Skin Conditions on the Allergic Skin Reactivity to Epicutaneous Allergen Exposure Completed NCT01628484 Phase 1
33 A RANDOMIZED, MULTIPLE DOSE, DOSE-ESCALATION, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE I TRIAL INVESTIGATING THE OPTIMAL SAFE DOSE OF ALK RAGWEED TABLET AMBROSIA ARTEMISIIFOLIA IN ADULT SUBJECTS WITH SEASONAL RHINOCONJUNCTIVITIS CAUSED BY RAGWEED POLLEN ALLERGY Completed NCT00330083 Phase 1
34 A Pre-Season,Randomized,Single-blind,Placebo-controlled,Parallel-group Study to Determine Tolerability+Safety of a New Cumulative Dose of GrassMATAMPL Compared With Placebo in Patients With Seasonal Allergic Rhinoconjunctivitis Due to Grass Pollen Allergy Completed NCT03931993 Phase 1
35 A Pre-season, Single Site, Single-blind, Parallel Group, Randomized Study to Determine the Tolerability and Safety of Two New Cumulative Doses of Modified Grass Allergens Adsorbed to L-tyrosine With Monophosphoryl Lipid A Adjuvant (Corixa), Phenol Preserved (Grass MATA MPL); Allergy Therapeutics, (UK) Ltd., Compared With Placebo in Patients With Seasonal Allergic Rhinoconjunctivitis Due to Grass Pollen Allergy. Completed NCT02557633 Phase 1
36 A Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety and Tolerability of Subcutaneous Immunotherapy With DM-101 in Adults With Birch Pollen Allergy Active, not recruiting NCT04266028 Phase 1
37 Effect of the Nasal Provocation on the Breathing Style and on the Calibration of Respiratory Effort Belts Unknown status NCT02146300
38 CRD and mHealth for Pollen Allergy in Southern Europe. A Multicenter Observational Study Unknown status NCT03636919
39 Observational Study With PASCALLERG ® in Patients With Hay Fever Completed NCT01660737
40 Probiotics for Reduction Of Markers In Subjects With Allergy Completed NCT01137357
41 Evaluation of High Speed Laser Doppler Imaging Technology to Quantify Skin Prick Tests in Allergic Volunteers Completed NCT02619331
42 Investigation of T-regulatory Cells After Subcutaneous Immunotherapy Completed NCT01830673
43 Does Medicinal Mushroom Agaricus Blazei Protect Against Allergy and Asthma? Completed NCT03198455
44 Comparison of the Influence of Different Skin Conditions on the Allergic Skin Reactivity to Epicutanous Allergen Exposure Completed NCT02074930
45 Long-term Follow-up of a Multicentre, Randomized, Double-blind, Placebo-controlled Trial (AN004T) Assessing the Efficacy and Tolerability of 2 Dosing Regimens of AllerT in Adult Subjects Allergic to Birch Pollen Completed NCT02143583
46 Changes in Specific Immunoglobulin and Blood Basophil Activity During Subcutaneous Immunotherapy in Patients With Allergic Rhinitis Due to Grass Pollen Allergy - a Prospective Randomized Controlled Study Completed NCT01085526 Alutard phl prat
47 Non-interventional Study A Multicentre Observational Study for Revaccination With Pollinex® Quattro in Patients With a Recurrent Grass Pollen Allergy Completed NCT02579720
48 Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens Recruiting NCT04435678
49 Investigating the Association of Iron and Pollen Allergy in Female Subjects Studie Zur Wirkung Von Eisen Auf Pollenallergikerinnen Active, not recruiting NCT03816800
50 Identification of Allergen-reactive Antibodies in the Blood of Pollen Allergic Patients Enrolling by invitation NCT03727399

Search NIH Clinical Center for Pollen Allergy

Inferred drug relations via UMLS 70 / NDF-RT 51 :


desloratadine
levocetirizine
levocetirizine dihydrochloride

Genetic Tests for Pollen Allergy

Anatomical Context for Pollen Allergy

MalaCards organs/tissues related to Pollen Allergy:

40
Skin, Eye, T Cells, Breast, Prostate, B Cells, Thymus

Publications for Pollen Allergy

Articles related to Pollen Allergy:

(show top 50) (show all 4018)
# Title Authors PMID Year
1
Development of a solid-supported cysteinyl probe for the isolation of electrophiles from plant pollen extracts. 61
33773702 2021
2
Identification of peroxidase-1 and beta-glucosidase as cross-reactive wheat allergens in grass pollen-related wheat allergy. 61
33616048 2021
3
Trajectories of asthma and allergies from 7 years to 53 years and associations with lung function and extrapulmonary comorbidity profiles: a prospective cohort study. 61
33217367 2021
4
Disease severity and trigger factors in Danish children with atopic dermatitis: a nationwide study. 61
33078461 2021
5
Eyelid dermatitis in patients referred for patch testing: Retrospective analysis of North American Contact Dermatitis Group data, 1994-2016. 61
32679276 2021
6
Children with atopic eczema experiencing increased disease severity in the pollen season more often have hay fever at a young age and a dark skin type. 61
33404119 2021
7
The evolution of allergy immunotherapy. 61
33271297 2021
8
Allergome-wide peptide microarrays enable epitope deconvolution in allergen-specific immunotherapy. 61
32791163 2021
9
Characterization of allergenicity of Platanus pollen allergen a 3 (Pla a 3) after exposure to NO2 and O3. 61
33735791 2021
10
Intralymphatic immunotherapy improves grass pollen allergic rhinoconjunctivitis: A 3-year randomized placebo-controlled trial. 61
32679209 2021
11
Preventive Effect of Allergen Immunotherapy on Asthma and New Sensitizations. 61
33746088 2021
12
Poststratification as a suitable approach to generalize findings of two cross-sectional studies along the Bavarian compulsory school entrance examination: An exemplary poststratified analysis for asthma, hay fever and wheezing. 61
33740566 2021
13
House dust microbiota in relation to adult asthma and atopy in a US farming population. 61
32615170 2021
14
Gestational hypertension and childhood atopy: a Millennium Cohort Study analysis. 61
33770273 2021
15
Prevalence of adult eczema, hay fever, and asthma, and associated risk factors: a population-based study in the northern Grassland of China. 61
33750462 2021
16
A survey on the health status of Dutch scuba diving instructors. 61
33761537 2021
17
Echinacea purpurea water extracts suppress the release of chemical mediators from mast cells. 61
33686410 2021
18
Development of an improved method to estimate the days of continuous drug ingestion, based on the micro-segmental hair analysis. 61
33682351 2021
19
Increased nasal Streptococcus pneumoniae presence in Western environment associated with allergic conditions in Chinese immigrants. 61
33725492 2021
20
Predicting the severity of the grass pollen season and the effect of climate change in Northwest Europe. 61
33771862 2021
21
Environmental DNA reveals links between abundance and composition of airborne grass pollen and respiratory health. 61
33711254 2021
22
Cloning, expression and immunological characterisation of Coc n 1, the first major allergen from Coconut pollen. 61
33486354 2021
23
Exposure to green space and pollen allergy symptom severity: A case-crossover study in Belgium. 61
33812114 2021
24
Variability of grass pollen allergy symptoms throughout the season: Comparing symptom data profiles from the Patient's Hayfever Diary from 2014 to 2016 in Vienna (Austria). 61
33717397 2021
25
Amaranthaceae pollen grains as indicator of climate change in Lublin (Poland). 61
33271139 2021
26
Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response. 61
33450188 2021
27
Oral birch pollen immunotherapy with apples: Results of a phase II clinical pilot study. 61
33621436 2021
28
Bet v 1 contiguous overlapping peptides anchored to virosomes with TLR4 agonist enhance immunotherapy efficacy in mice. 61
33368719 2021
29
Simplified AIT for allergy to several tree pollens-Arguments from the immune outcome analyses following treatment with SQ tree SLIT-tablet. 61
33207015 2021
30
Atopic diseases of the parents predict the offspring's atopic sensitization and food allergy. 61
33527507 2021
31
Association between selected urinary heavy metals and asthma in adults: a retrospective cross-sectional study of the US National Health and Nutrition Examination Survey. 61
32978737 2021
32
Prevalence and trend of allergen sensitization in patients with nummular (discoid) eczema referred for patch testing: North American Contact Dermatitis Group data, 2001-2016. 61
33634511 2021
33
Allergen-specific immunotherapy induces the suppressive secretoglobin 1A1 in cells of the lower airways. 61
33528894 2021
34
[Diseases connected with work in hay in Iceland. Haymaking and old data on such diseases]. 61
33501922 2021
35
Exposure to indoor and outdoor air pollution from solid fuel combustion and respiratory outcomes in children in developed countries: a systematic review and meta-analysis. 61
33017761 2021
36
What does climate change mean for people with pollen allergy? 61
33617068 2021
37
High-affinity Bet v 1-specific secretory IgA antibodies in nasal fluids protect against birch pollen allergy. 61
33594667 2021
38
Forecast for Pollen Allergy: A Review from Field Observation to Modeling and Services in Korea. 61
33228869 2021
39
Climate Change and Pollen Allergy in India and South Asia. 61
33228871 2021
40
Walnut Allergy Across Europe: Distribution of Allergen Sensitization Patterns and Prediction of Severity. 61
32916320 2021
41
Establishment and characterization of murine models of asthma and subcutaneous immunotherapy for Humulus pollen allergy. 61
33434413 2021
42
CYPRESS POLLEN SESITIZATION IN GEORGIA: CLINICAL AND MOLECULAR CHARACTERISTICS. 61
33658417 2021
43
Measuring Temporal Instability of Momentary Affect, Subjective Health and Symptom Burden Depending on Environmental Parameters-An Ambulatory Assessment Study in Persons with Hay Fever. 61
33419198 2021
44
Impact of elevated air temperature and drought on pollen characteristics of major agricultural grass species. 61
33770086 2021
45
Efficacy of sublingual immunotherapy tablets in dust mite and pollen allergy. 61
33404387 2021
46
Intradermal Phleum pratense allergoid immunotherapy. Double-blind, randomized, placebo-controlled trial. 61
32946612 2020
47
Pollen-food allergy syndrome in children. 61
32403897 2020
48
Discovery to Launch of Anti-allergy (Emadine; Patanol/Pataday/Pazeo) and Anti-glaucoma (Travatan; Simbrinza) Ocular Drugs, and Generation of Novel Pharmacological Tools Such as AL-8810. 61
33344909 2020
49
Asthma, atopy and serious psychological distress: prevalence and risk factors among young people in the Melbourne atopy cohort study. 61
31380704 2020
50
[Analysis of sensitization characteristics of artemisia pollen in the Inner Mongolian grassland region of China]. 61
33254342 2020

Variations for Pollen Allergy

Expression for Pollen Allergy

Search GEO for disease gene expression data for Pollen Allergy.

Pathways for Pollen Allergy

Pathways related to Pollen Allergy according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.85 RNASE3 PRG2 MPO IL5 IL4R IL3RA
2
Show member pathways
13.19 IL5 IL4R IL3RA IL3 IL13 IGHE
3 12.68 IL5 IL4R IL3RA IL3 IL13
4 12.37 MPO IL3 FOXP3 ENPP3 CD63
5
Show member pathways
12.16 IL5 IL4R IL3RA IL3 IL13
6
Show member pathways
11.97 RNASE3 PRG2 IL5 IL3 IL13 ICAM1
7 11.79 IL4R IL13 IGHE ICAM1
8 11.64 IL5 IL13 ICAM1
9 11.62 IL5 IL4R IL3RA IL3
10
Show member pathways
11.58 IL5 IL3 FOXP3
11 11.51 IL5 ICAM1 FOXP3
12 11.47 IL5 IL4R IGHE
13 11.42 MPO IL5 IL3RA IL3 CD164
14 11.12 IL5 IL4R IL13 FOXP3
15 11.04 IL5 IL3 IL13
16 10.77 MPO ICAM1
17 10.51 IL5 IL4R IL13

GO Terms for Pollen Allergy

Cellular components related to Pollen Allergy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 RNASE3 MPO IL5 IL4R IL3 IL13
2 external side of plasma membrane GO:0009897 9.55 IL3RA IL13 IGHE ICAM1 ENPP3
3 extracellular region GO:0005576 9.4 RNASE3 PRG2 MPO IL5 IL4R IL3

Biological processes related to Pollen Allergy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neutrophil degranulation GO:0043312 9.83 RNASE3 PRG2 MPO EPX CD63
2 positive regulation of cold-induced thermogenesis GO:0120162 9.65 IL4R IL13 ADRB2
3 defense response to bacterium GO:0042742 9.65 RNASE3 PRG2 MPO IGHE EPX
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.63 IL5 IL3 ICAM1
5 response to lipopolysaccharide GO:0032496 9.62 MPO IL13 ICAM1 FOXP3
6 immune response GO:0006955 9.5 PRG2 IL5 IL4R IL3 IL13 IGHE
7 positive regulation of mast cell degranulation GO:0043306 9.4 IL4R IL13
8 negative regulation of interleukin-5 production GO:0032714 9.37 FOXP3 EPX
9 positive regulation of immunoglobulin production GO:0002639 9.33 IL5 IL4R IL13
10 cytokine-mediated signaling pathway GO:0019221 9.17 IL5 IL4R IL3RA IL3 IL13 IGHE

Sources for Pollen Allergy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....